Capsoil is an innovative nanotechnology company with an advanced patented process that converts oils in their full spectrum into nanometric powder. Capsoil’s ground-breaking technology is applicable to many industries including Pharmaceuticals, Food, Nutraceuticals, Cosmetics and Medical Cannabis.

CannaPowder, Inc. has developed revolutionary nanometric cannabis powders to enable cannabis users, whether for medical or recreational purposes to increase dramatically bioavailability of cannabinoids.

Lipicare develops micro-emulsion technology in order to facilitate the delivery of drug molecules, especially lipophilic drug molecules, to the eye.The micro-emulsion technology is designed as a drug delivery platform and its unique pharmaceutical advantages include:Incorporation of lipophilic drug moleculesLonger contact time between the drug and the eye surfaceCombines hydrophilic and lipophilic molecules in one preparationPresent dual treatment in one dropPresent slow release capabilities with lipid solubility drugshttp://www.bio-light.co.il/lipicare-micro-emulsion-technology-for-delivering-ophthalmic-drugs/

The firm is highly involved in the pharmacy market in Israel with new strategic for the modern pharmacy and pharmacist. The firm runs a Medication Consulting Centre in Tel-Aviv, patients from all over the country are advised by clinical pharmacists about their medication and their health.As an owner of a pharmacy and a pharmacist, Rafael is an active member at the Israeli Pharmaceutical Association with a special interest in designing the strategic and the future of the pharmacies in Israel.

The company has developed a patented formulation, as a medical device, for the non-surgical treatment of skin lesions. This innovative formulation lacks severe drawbacks of past technologies. Non-surgical treatment of skin lesions with destructive modalities is a highly common clinic procedure performed by Dermatologists, without the possibility of obtaining a histological diagnosis of the destructed lesion. Past technologies of chemical destruction and fixation of lesions had severe drawbacks and their use was abandoned. The company had completed successful pre clinical studies in animals and in human tissues. Based on these encouraging results, the Helsinki Committee of the Israeli Ministry of Health approved a clinical study of our device in human subjects in the Hillel Yaffe Medical Center.